May 26, 2023 7:00 am EDT Castle Biosciences’ Abstracts at Digestive Disease Week (DDW) Annual Meeting Selected as “Posters of Distinction” by the American Gastroenterological Association (AGA) Institute Council
May 15, 2023 7:00 am EDT Castle Biosciences’ TissueCypher® Barrett's Esophagus Test Receives 2023 MedTech Breakthrough Award for Artificial Intelligence Innovation
May 3, 2023 7:00 am EDT Study Demonstrates Use of DecisionDx®-Melanoma to Guide Treatment Decisions Resulted in Earlier Detection of Melanoma with Decreased Metastatic Tumor Burden Compared to Patients Without Surveillance Imaging Studies
Apr 28, 2023 7:00 am EDT Castle Biosciences Collaborates with IMPACT Melanoma to Provide Free Sunscreen to Cyclists Participating in the Bike MS: Texas MS 150 2023 Cycling Event
Apr 25, 2023 7:00 am EDT DecisionDx®-Melanoma Provides Improved Risk Stratification Over American Joint Committee on Cancer (AJCC) Staging Alone in Stage I Melanoma Patients
Apr 20, 2023 7:00 am EDT TissueCypher® Test Results Can Increase the Likelihood of Appropriate Management Decisions for Barrett’s Esophagus Patients with Low-Grade Dysplasia
Apr 19, 2023 7:00 am EDT Castle Biosciences to Release First Quarter 2023 Financial Results and Host Conference Call on Wednesday, May 3
